Pharmacodynamics of eftrenonacog-alfa (rFIX-Fc) in severe hemophilia B patients: A real-life study

Atsou, Sénadé; Furlan, F.; Duchemin, Jérôme; Ellouze, Syrine; Sourdeau, Élise; Launois, Amélie; Roussel-Robert, V.; Stieltjes, N.; Combe, S.; Fontenay, Michaëla; Curis, Emmanuel; Jourdi, Georges

doi:10.1016/j.ejphar.2020.173764

Cited by 3 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thrombin peak height and ETP were the following parameters that decreased over time after replacement therapy. However, bleeding was not assessed in this study ( 67 ).…”

Section: Bleeding Disordersmentioning

confidence: 98%

Thrombin generation assays to personalize treatment in bleeding and thrombotic diseases

Valke

Rijpma

Meijer

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Treatment of bleeding and thrombotic disorders is highly standardized and based on evidence-based medicine guidelines. These evidence-based treatment schemes are well accepted but may lead to either insufficient treatment or over-dosing, because the individuals’ hemostatic properties are not taken into account. This can potentially introduce bleeding or thrombotic complications in individual patients. With the incorporation of pharmacokinetic (PK) and pharmacodynamic (PK-PD) parameters, based on global assays such as thrombin generation assays (TGAs), a more personalized approach can be applied to treat either bleeding or thrombotic disorders. In this review, we will discuss the recent literature about the technical aspects of TGAs and the relation to diagnosis and management of bleeding and thrombotic disorders. In patients with bleeding disorders, such as hemophilia A or factor VII deficiency, TGAs can be used to identify patients with a more severe bleeding phenotype and also in the management with non-replacement therapy and/or bypassing therapy. These assays have also a role in patients with venous thrombo-embolism, but the usage of TGAs in patients with arterial thrombosis is less clear. However, there is a potential role for TGAs in the monitoring of (long-term) antithrombotic therapy, for example with the use of direct oral anticoagulants. Finally this review will discuss controversies, limitations and knowledge gaps in relation to the introduction of TGAs to personalize medicine in daily medical practice.

show abstract

“…Thrombin peak height and ETP were the following parameters that decreased over time after replacement therapy. However, bleeding was not assessed in this study ( 67 ).…”

Section: Bleeding Disordersmentioning

confidence: 98%

Thrombin generation assays to personalize treatment in bleeding and thrombotic diseases

Valke

Rijpma

Meijer

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

Pharmacokinetic–Pharmacodynamic Modelling in Hemophilia A: Relating Thrombin and Plasmin Generation to Factor VIII Activity After Administration of a VWF/FVIII Concentrate

Valke,

Cloesmeijer,

Mansouritorghabeh

et al. 2024

Eur J Drug Metab Pharmacokinet

View full text Add to dashboard Cite

Engineered polyspecific antibodies: A new frontier in the field of immunotherapeutics

Sandeep,

Shinde,

Ahmed

et al. 2023

Immunology

View full text Add to dashboard Cite

The 21st‐century beginning remarked with the huge success of monospecific MAbs, however, in the last couple of years, polyspecific MAbs (PsAbs) have been an interesting topic and show promise of being biobetter than monospecific MAbs. Polyspecificity, in which a single antibody serves multiple specific target binding, has been hypothesized to contribute to the development of a highly effective antibody repertoire for immune defence. This polyspecific MAb trend represents an explosion that is gripping the whole pharmaceutical industry. This review is concerned with the current development and quality enforcement of PsAbs. All provided literature on monospecific MAbs and polyspecific MAbs (PsAbs) were searched using various electronic databases such as PubMed, Google Scholar, Web of Science, Elsevier, Springer, ACS, Google Patent and books via the keywords Antibody engineering, Polyspecific antibody, Conventional antibody, non‐conventional antibody, and Single domain antibody. In the literature, there are more than 100 different formats to construct PsAb by quadroma technology, chemical conjugation and genetic engineering. Till March 2023, nine PsAb have been approved around the world, and around 330 are in advanced developmental stages, showing the dominancy of PsAb in the growing health sector. Recent advancements in protein engineering techniques and the fusion of non‐conventional antibodies have made it possible to create complex PsAbs that demonstrate higher stability and enhanced potency. This marks the most significant achievement for cancer immunotherapy, in which PsAbs have immense promise. It is worth mentioning that seven out of the nine PsAbs have been approved as anti‐cancer therapy. As PsAbs continue to acquire prominence, they could pave the way for the development of novel immunotherapies for multiple diseases.

show abstract

Pharmacodynamics of eftrenonacog-alfa (rFIX-Fc) in severe hemophilia B patients: A real-life study

Cited by 3 publications

References 30 publications

Thrombin generation assays to personalize treatment in bleeding and thrombotic diseases

Thrombin generation assays to personalize treatment in bleeding and thrombotic diseases

Pharmacokinetic–Pharmacodynamic Modelling in Hemophilia A: Relating Thrombin and Plasmin Generation to Factor VIII Activity After Administration of a VWF/FVIII Concentrate

Engineered polyspecific antibodies: A new frontier in the field of immunotherapeutics

Contact Info

Product

Resources

About